Javascript must be enabled to continue!
Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: Do antipsychotics influence learning to ignore irrelevant stimuli via both Drd-2 and non-D
View through CrossRef
Whether the dopamine Drd-2 receptor is necessary for the behavioural action of antipsychotic drugs is an important question, as Drd-2 antagonism is responsible for their debilitating motor side effects. Using Drd-2 null mice ( Drd
2
-/-) it has previously been shown that Drd-2 is not necessary for antipsychotic drugs to reverse D-amphetamine disruption of latent inhibition (LI), a behavioural measure of learning to ignore irrelevant stimuli. Weiner’s ‘two-headed’ model indicates that antipsychotics not only reverse LI disruption, ‘disrupted LI’, but also potentiate LI when low/absent in controls, ‘persistent’ LI. We investigated whether antipsychotic drugs haloperidol or clozapine potentiated LI in wild-type controls or Drd
2
-/-. Both drugs potentiated LI in wild-type but not in Drd
2
-/- mice, suggesting moderation of this effect of antipsychotics in the absence of Drd-2. Haloperidol potentiated LI similarly in both Drd
1
-/- and wild-type mice, indicating no such moderation in Drd
1
-/-. These data suggest that antipsychotic drugs can have either Drd-2 or non-Drd-2 effects on learning to ignore irrelevant stimuli, depending on how the abnormality is produced. Identification of the non-Drd-2 mechanism may help to identify novel non-Drd2 based therapeutic strategies for psychosis.
Title: Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: Do antipsychotics influence learning to ignore irrelevant stimuli via
both
Drd-2 and non-D
Description:
Whether the dopamine Drd-2 receptor is necessary for the behavioural action of antipsychotic drugs is an important question, as Drd-2 antagonism is responsible for their debilitating motor side effects.
Using Drd-2 null mice ( Drd
2
-/-) it has previously been shown that Drd-2 is not necessary for antipsychotic drugs to reverse D-amphetamine disruption of latent inhibition (LI), a behavioural measure of learning to ignore irrelevant stimuli.
Weiner’s ‘two-headed’ model indicates that antipsychotics not only reverse LI disruption, ‘disrupted LI’, but also potentiate LI when low/absent in controls, ‘persistent’ LI.
We investigated whether antipsychotic drugs haloperidol or clozapine potentiated LI in wild-type controls or Drd
2
-/-.
Both drugs potentiated LI in wild-type but not in Drd
2
-/- mice, suggesting moderation of this effect of antipsychotics in the absence of Drd-2.
Haloperidol potentiated LI similarly in both Drd
1
-/- and wild-type mice, indicating no such moderation in Drd
1
-/-.
These data suggest that antipsychotic drugs can have either Drd-2 or non-Drd-2 effects on learning to ignore irrelevant stimuli, depending on how the abnormality is produced.
Identification of the non-Drd-2 mechanism may help to identify novel non-Drd2 based therapeutic strategies for psychosis.
Related Results
Evolution of dopamine receptors: phylogenetic evidence suggests a later origin of the DRD
2l
and DRD
4rs
dopamine receptor gene lineages
Evolution of dopamine receptors: phylogenetic evidence suggests a later origin of the DRD
2l
and DRD
4rs
dopamine receptor gene lineages
Dopamine receptors are integral membrane proteins whose endogenous ligand is dopamine. They play a fundamental role in the central nervous system and dysfunction of dopaminergic ne...
Phylogenetic evidence suggests a later origin of the DRD
2l
and DRD
4rs
dopamine receptor gene lineages
Phylogenetic evidence suggests a later origin of the DRD
2l
and DRD
4rs
dopamine receptor gene lineages
Dopamine receptors are integral membrane proteins whose endogenous ligand is dopamine. They play a fundamental role in the central nervous system and dysfunction of dopaminergic ne...
Supporting successful clozapine treatment
Supporting successful clozapine treatment
The overall objective of this thesis is to support successful clozapine treatment, by firstly expanding the knowledge on the predictability of early clozapine discontinuation, seco...
Efficacy and safety of clozapine combination with different antipsychotics in schizophrenia: a systematic review
Efficacy and safety of clozapine combination with different antipsychotics in schizophrenia: a systematic review
Schizophrenia is a severe and chronic mental disorder, where antipsychotics are used as the main therapy. Antipsychotics are commonly used in combination, especially in refractory ...
Community Clozapine Initiation Practice
Community Clozapine Initiation Practice
AimsTo establish the proportion of CMHT Preston service users with schizophrenia who met the NICE standard (CG 178) of being offered clozapine after inadequate response to treatmen...
Clozapine Prescribing in the General Hospitals
Clozapine Prescribing in the General Hospitals
Aims:
Clozapine is an effective treatment for adults with schizophrenia, who have not responded to two other antipsychotic medications. However, there are chall...
A Systematic Review of Treatment Outcome in Patients with Dopa‐responsive Dystonia (DRD) and DRD‐Plus
A Systematic Review of Treatment Outcome in Patients with Dopa‐responsive Dystonia (DRD) and DRD‐Plus
AbstractBackgroundDopa‐responsive dystonia (DRD) and DRD‐plus are inherited metabolic disorders of the dopamine synthetic pathway that have considerable clinical, biochemical, and ...
Assessment of treatment outcomes and associated factors among patients treated with clozapine at amanuel mental specialized hospital, Addis Ababa, Ethiopia
Assessment of treatment outcomes and associated factors among patients treated with clozapine at amanuel mental specialized hospital, Addis Ababa, Ethiopia
Background
Clozapine is a medication used in psychiatry. It is the first atypical antipsychotic drug and the most effective in treatment resistant cases of schizophrenia and schizo...

